Andrew Krivoshik (Astellas)

Astel­las and Seagen's Pad­cev wins full FDA ap­proval, notch­ing ex­pand­ed la­bel in tough-to-crack urothe­lial can­cer

Two years af­ter Seagen and Astel­las won a con­di­tion­al FDA ap­proval to tar­get urothe­lial can­cer, the pair’s Pad­cev drug has been giv­en a full en­dorse­ment …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.